Skip to content

Study · In vitro (cells) · 1990

6 results

Thymosin alpha 1 and thymosin beta 4 modulate human colonic lamina propria lymphocyte function.

Elitsur Y, Mutchnick MG, Sakr WA, Luk GD

Immunopharmacology1 Sept 1990Cited by 4 (Europe PMC)

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Activity measurement

    In human colonic lamina propria lymphocytes, thymosin alpha‑1 suppressed thymidine incorporation.

    In plain wordsIn lab tests on human gut immune cells, thymosin alpha‑1 reduced cell growth compared with no peptide.

    Outcome
    DecreaseThymidine incorporation into lamina propria lymphocytes
    Study

    humann = 18

    colonic lamina propria lymphocytes
    Comparator
    Culture without the peptide
    Outcome group
    Immune response · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    We found that both peptides suppressed thymidine incorporation into LPL.
    1 context sentence
    Summary · context
    LPL from eighteen human colon specimens were cultured in the presence or absence of thymosin alpha 1 and thymosin beta 4.
  2. 02LabIn vitro (cells)Activity measurement

    In phorbol ester and ionomycin stimulated human colonic lymphocytes, thymosin alpha‑1 did not change thymidine incorporation.

    In plain wordsIn lab tests on stimulated human gut immune cells, thymosin alpha‑1 did not change cell growth.

    Outcome
    No significant changeThymidine incorporation in PDB and ionomycin stimulated lymphocytes
    Study

    humann = 18

    colonic lamina propria lymphocytes
    Comparator
    Stimulated culture without the peptide
    Outcome group
    Immune response · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    However, thymosin alpha 1 and thymosin beta 4 did not alter thymidine incorporation into phorbol ester (PDB) and calcium ionophore (ionomycin)-stimulated LPL.
    1 context sentence
    Summary · context
    LPL from eighteen human colon specimens were cultured in the presence or absence of thymosin alpha 1 and thymosin beta 4.
  3. 03LabIn vitro (cells)Activity measurement

    In Con A stimulated human colonic lymphocytes, thymosin alpha‑1 did not change ornithine decarboxylase activity.

    In plain wordsIn lab tests on stimulated human gut immune cells, thymosin alpha‑1 did not change this enzyme activity.

    Outcome
    No significant changeOrnithine decarboxylase activity in Con A stimulated lymphocytes
    Study

    humann = 18

    colonic lamina propria lymphocytes
    Comparator
    Stimulated culture without the peptide
    Outcome group
    Immune response · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Furthermore, thymosin alpha 1 and thymosin beta 4 also did not alter ODC activity in Con A-stimulated LPL.
    1 context sentence
    Summary · context
    LPL from eighteen human colon specimens were cultured in the presence or absence of thymosin alpha 1 and thymosin beta 4.
  4. 04LabIn vitro (cells)Activity measurement

    In human colonic lamina propria lymphocytes, thymosin beta‑4 suppressed thymidine incorporation.

    In plain wordsIn cells from human colon, thymosin beta‑4 reduced lymphocyte growth.

    Outcome
    DecreaseLPL thymidine incorporation
    Study

    humann = 18

    human colonic lamina propria lymphocytes (LPL)
    Comparator
    Cultures without peptide
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    We found that both peptides suppressed thymidine incorporation into LPL.
    1 context sentence
    Summary · context
    LPL from eighteen human colon specimens were cultured in the presence or absence of thymosin alpha 1 and thymosin beta 4.
  5. 05LabIn vitro (cells)Activity measurement

    In human colonic lamina propria lymphocytes stimulated with phorbol ester and ionomycin, thymosin beta‑4 did not alter thymidine incorporation.

    In plain wordsIn stimulated cells from human colon, thymosin beta‑4 did not change lymphocyte growth.

    Outcome
    No significant changeThymidine incorporation in PDB- and ionomycin-stimulated LPL
    Study

    humann = 18

    human colonic lamina propria lymphocytes (LPL)
    Comparator
    Cultures without peptide
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    However, thymosin alpha 1 and thymosin beta 4 did not alter thymidine incorporation into phorbol ester (PDB) and calcium ionophore (ionomycin)-stimulated LPL.
    1 context sentence
    Summary · context
    LPL from eighteen human colon specimens were cultured in the presence or absence of thymosin alpha 1 and thymosin beta 4.
  6. 06LabIn vitro (cells)Activity measurement

    In Con A-stimulated human colonic lamina propria lymphocytes, thymosin beta‑4 did not alter ornithine decarboxylase activity.

    In plain wordsIn stimulated cells from human colon, thymosin beta‑4 did not change the activity of the enzyme ODC.

    Outcome
    No significant changeODC activity in Con A-stimulated LPL
    Study

    humann = 18

    human colonic lamina propria lymphocytes (LPL)
    Comparator
    Cultures without peptide
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Furthermore, thymosin alpha 1 and thymosin beta 4 also did not alter ODC activity in Con A-stimulated LPL.
    1 context sentence
    Summary · context
    LPL from eighteen human colon specimens were cultured in the presence or absence of thymosin alpha 1 and thymosin beta 4.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 4Current

    12 Oct 2026, 18:17 UTC

    Study data updated · source update from Europe PMC

  2. Version 3

    10 Oct 2026, 08:55 UTC

    Study results updated

  3. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  4. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.